Contrasting Zomedica (OTC:ZOMDF) & Petros Pharmaceuticals (NASDAQ:PTPI)

Institutional and Insider Ownership

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 8.9% of Zomedica shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of Zomedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Petros Pharmaceuticals and Zomedica”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11 million	0.05	-$8.16 million	($39.69)	0.00
Zomedica	N/A	N/A	N/A	($0.10)	-1.15

Zomedica has lower revenue, but higher earnings than Petros Pharmaceuticals. Zomedica is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Petros Pharmaceuticals and Zomedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Zomedica	N/A	N/A	N/A

Risk and Volatility

Petros Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Zomedica has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

Petros Pharmaceuticals beats Zomedica on 5 of the 8 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.